Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy…
Multiple myeloma patients whose cancer progresses early after first-line therapy have a greater economic burden compared to those whose disease progresses later, a recent study…
Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple…
Prescribing information for Kyprolis (carfilzomib) in the U.S. will now include positive survival data from the ASPIRE Phase 3 clinical trial, which found treatment significantly…
Genetic analysis of multiple myeloma DNA from two different sources present in blood samples provides researchers equally relevant cancer information as more invasive bone marrow…
Adding Empliciti (elotuzumab) to a combination of Pomalyst (pomalidomide) and dexamethasone significantly delays disease worsening or death in myeloma patients who failed to respond to previous treatment,…
A Phase 1b trial testing a combination of Reolysin (pelareorep), Velcade (bortezomib) and dexamethasone in multiple myeloma patients who failed to respond to previous therapy…
While the best described cancer mutations are in regions that provide instructions to make proteins, most mutations actually happen in the noncoding regions of our…
Updated clinical trial data show that selinexor added to standard therapies can benefit multiple myeloma patients who have failed multiple prior lines of therapy, Karyopharm…
Trillium Therapeutics recently dosed the first patient in its Phase 1 clinical trial of TTI-622, a checkpoint inhibitor of the immune system being developed…
